Results 21 to 30 of about 20,043 (161)

Chronic toxicity and environmental risk assessment of antivirals in Ceriodaphnia dubia and Raphidocelis subcapitata

Water Science and Technology, 2021
Antiviral drugs are a class of medications used for treating viral infections. Due to their widespread use, especially in cases of pandemics and limited human metabolism, antivirals have been detected in multiple environmental matrices.
L. C. Almeida, A. C. Mattos, C. P. G. Dinamarco, N. G. Figueiredo, D. M. Bila   +4 more
doaj   +1 more source

Effect of Efavirenz on UDP-Glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 Activities in Human Liver Microsomes

Molecules, 2012
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used for the treatment of human immunodeficiency virus type 1 infections. Drug interactions of efavirenz have been reported due to in vitro inhibition of CYP2C9, CYP2C19, CYP3A4, and UDP ...
Hye Suk Lee, Hyeri Lee, Sae Rom Lim, Jeong Han Kim, Hye Young Ji   +4 more
doaj   +1 more source

Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid

Southern African Journal of HIV Medicine
Background: CYP2B6 slow metabolisers have higher efavirenz concentrations, which are further increased by isoniazid inhibiting efavirenz’s accessory metabolic pathway.
Jessica Taylor, Gary Maartens, Simiso Sokhela, Nomathemba Chandiwana, Godspower Akpomiemie, Francois Venter, Phumla Sinxadi   +6 more
doaj   +1 more source

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

BMC Infectious Diseases, 2018
Background Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive patients co-infected with tuberculosis (HIV/TB).
Yanink Caro-Vega, Anna Schultze, Anne Marie W. Efsen, Frank A. Post, Alexander Panteleev, Aliaksandr Skrahin, Jose M. Miro, Enrico Girardi, Daria N. Podlekareva, Jens D. Lundgren, Juan Sierra-Madero, Javier Toibaro, Jaime Andrade-Villanueva, Simona Tetradov, Jan Fehr, Joan Caylà, Marcelo H. Losso, Robert F. Miller, Amanda Mocroft, Ole Kirk, Brenda Crabtree-Ramírez   +20 more
doaj   +1 more source

Developmental abnormalities and growth patterns in juvenile Oreochromis mossambicus chronically exposed to efavirenz

Emerging Contaminants, 2022
Efavirenz is an antiretroviral drug (ARV) used for the treatment of Human Immunodeficiency Virus (HIV/AIDS) infections. The effects efavirenz may have on mammals is known, however, little is known about the effects on non-target aquatic organisms ...
Saisha Kowlaser, Irene Barnhoorn, Ina Wagenaar   +2 more
doaj   +1 more source

Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers

Current Therapeutic Research, 2014
Background: Efavirenz exhibits multiple interactions with drug-metabolizing enzymes and transporters, and for this reason efavirenz-based HIV therapy is associated with altered pharmacokinetics of coadministered drugs.
Ingrid F. Metzger, PhD, Troy C. Quigg, MD, Noam Epstein, Abdulateef O. Aregbe, MD, Nancy Thong, John T. Callaghan, MD, PhD, David A. Flockhart, MD, PhD, Anne T. Nguyen, Colleen K. Stevens, Samir K. Gupta, Zeruesenay Desta, PhD   +10 more
doaj   +1 more source

Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. [PDF]

PLoS ONE, 2014
OBJECTIVES: Plasma efavirenz concentrations in HIV-infected patients with tuberculosis (TB) may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and concurrent rifampicin use.
Kuan-Yeh Lee, Shu-Wen Lin, Hsin-Yun Sun, Ching-Hua Kuo, Mao-Song Tsai, Bing-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Sui-Yuan Chang, Chien-Ching Hung   +9 more
doaj   +1 more source

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections [PDF]

Universa Medicina, 2009
The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny
doaj  

Induction of Multiple Drug Transporters by Efavirenz

Journal of Pharmacological Sciences, 2009
Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1. So far its effect on the expression of other transporters is unknown.
Johanna Weiss, Melanie Herzog, Sonja König, Caroline Henrike Storch, Nahal Ketabi-Kiyanvash, Walter Emil Haefeli   +5 more
doaj   +1 more source

Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment

Heliyon, 2021
Efavirenz is inhibitor of non-nucleoside reverse transcriptase enzyme; BCS class II drug. The objective of the present research was to prepare and evaluate nanosuspension of Efavirenz for the treatment of neuro-AIDS.
Smita Kakad, Sanjay Kshirsagar
doaj   +1 more source